ArticleScientific reports2025
EZH-2 expression and prognostic significance in patients with low-grade non-Hodgkin lymphoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EZH-2 overexpression or mutation is associated with various cancers, and there is a substantial academic literature on the role of EZH-2 and its mutant alleles in the pathogenesis of B-cell non-Hodgkin lymphomas (NHLs). The objective of the study was to examine the expression of EZH-2 in patients with low-grade NHL and to assess the effect of this expression on prognosis. The study included 140 pathologically diagnosed indolent NHL cases that met the established inclusion and exclusion criteria. The study assessed a number of factors, including age at diagnosis, gender, histological type of tumor, region of involvement, clinical stage, treatments received, response to treatment, final disease status, and EZH-2 expression rate. The risk of death is 1.87 times higher in patients with EZH-2 positivity (≥ 30% staining density ) for overall survival, while for disease-free survival, the risk of relapse or disease progression is 1.81 times higher in patients with EZH-2 positivity. EZH-2 positivity has been identified as an independent risk factor that significantly reduces survival, thereby worsening prognosis. These findings suggest that EZH-2 expression may be a valuable prognostic marker in indolent NHLs and may help guide treatment decisions in high-risk patient subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.